Literature DB >> 19456988

Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma.

Matthias May1, Sabine Brookman-Amissah, Friederike Kendel, Nina Knoll, Jan Roigas, Bernd Hoschke, Kurt Miller, Christian Gilfrich, Sandra Pflanz, Oliver Gralla.   

Abstract

OBJECTIVES: To determine the value of microvascular invasion, tumor size, and Fuhrman grade to predict the survival of patients with surgically resected renal cell carcinoma (RCC).
METHODS: A total of 771 consecutive patients (T1-4, Nx, M0) were retrospectively reviewed. For each patient with RCC, the prognostic Sao Paulo score (SPS) was calculated using the following variables: tumor size (>7 cm vs <or=7 cm), nuclear grading, and microvascular invasion. On the basis of SPS, patients were subdivided into low-risk (LR), intermediate-risk (IR), and high-risk (HR) groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Median follow-up was 80 months.
RESULTS: Median follow-up was 80 months. DFS rates after 5 years were 91.2%, 61.3%, and 51.9% in the original SPS LR, IR, and HR groups, respectively. CSS rates after 5 years were 94.3%, 79.8%, and 58.7%, respectively (P < 0.001). Each original SPS constituent revealed a significant influence on DFS and CSS in the multivariate analysis. By modification of the cut-off value of the maximum tumor size from 7 to 5 cm the predictive value of the SPS sum score was marginally enhanced. Using a cut-off value of 5 cm also resulted in a relatively better discrimination between the IR and the HR group regarding DFS and CSS.
CONCLUSIONS: Stratifying RCC patients by SPS into LR, IR, and HR groups provides a clinically useful tool for outcome analysis and risk assessment. However, the prognostic value of the SPS could be enhanced by including a maximum tumor size with a cut-off at 5 cm into the sum score.

Entities:  

Mesh:

Year:  2009        PMID: 19456988     DOI: 10.1111/j.1442-2042.2009.02319.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  [Organ and kidney function preservation in renal cell carcinoma].

Authors:  M Schenck; R Eder; H Rübben; C Niedworok; S Tschirdewahn
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

2.  Microvascular invasion as a prognostic indicator in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Hai Huang; Xiu-Wu Pan; Yi Huang; Dan-Feng Xu; Xin-Gang Cui; Lin Li; Yi Hong; Lu Chen; Yi Gao; Lei Yin
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.

Authors:  Walter Henriques da Costa; Rafael Malagoli Rocha; Isabela Werneck da Cunha; Francisco Paula da Fonseca; Gustavo Cardoso Guimaraes; Stenio de Cassio Zequi
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

4.  Factors affecting the time to recurrence after radical nephrectomy for localized renal cell carcinoma.

Authors:  Hee-Seo Son; Seung Hyun Jeon; Sung-Goo Chang
Journal:  Korean J Urol       Date:  2013-11-06

5.  Development and Validation of a Nomogram Predicting the Prognosis of Renal Cell Carcinoma After Nephrectomy.

Authors:  Mancheng Xia; Haosen Yang; Yusheng Wang; Keqiang Yin; Xiaodong Bian; Jiawei Chen; Weibing Shuang
Journal:  Cancer Manag Res       Date:  2020-06-11       Impact factor: 3.989

6.  Identification of a Somatic Mutation-Derived Long Non-Coding RNA Signatures of Genomic Instability in Renal Cell Carcinoma.

Authors:  Xisheng Fang; Xia Liu; Lin Lu; Guolong Liu
Journal:  Front Oncol       Date:  2021-10-05       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.